Background: To analyze the influence of oral contraceptive pill (OCP) pretreatment in intracytoplasmic sperm injection cycles among normoresponders in whom leuprolide acetate is preferred for that kind of gonadotropin-releasing hormone agonist. Methods: Between March 2001 and January 2010, a total of 821 cycles were pretreated with OCP in luteal-long leuprolide acetate in the IVF Center, Faculty of Medicine, University of Hacettepe. Of these, a total of 169 consecutive patients were selected for the final analyses according to the selection criteria (OCP group) and compared with 349 age-matched controls (Control group). The normoresponders were defined by the presence of 6–15 antral follicles in both ovaries. Results: Female age, body mass index, duration of infertility and antral follicle count were similar among both groups. Although the total dose of FSH used and duration of stimulation were similar, the maximal serum estradiol concentrations were higher in the OCP group than in the Control group (2,630.3 ± 1,568.0 vs. 2,166.5 ± 1,259.7 pg/ml, p = 0.001). The mean numbers of metaphase-II oocytes were 11.0 ± 6.2 versus 9.4 ± 5.2 in the OCP and Control groups, respectively (p = 0.004). The mean number of available day 3 embryos having ≧7 blastomeres was also higher in the OCP group (4.4 ± 3.3 vs. 3.5 ± 3.1, p = 0.013). However, the embryo transfer cancellation rate was noted to be higher in the OCP group, which is mainly due to fertilization failure and arrest during embryogenesis (6.5 vs. 2.9%, p = 0.049). The clinical pregnancy (36.7 vs. 38.3%) and implantation rates (21.8 vs. 20.6%) were comparable. Conclusion: These findings suggest that although pretreatment with an OCP might exaggerate ovarian response, the pregnancy rate does not fluctuate in leuprolide acetate cycles among normoresponders.

Griesinger G, Venetis CA, Marx T, Diedrich K, Tarlatzis BC, Kolibianakis EM: Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. Fertil Steril 2008;90:1055–1063.
Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL: Effects of pretreatment with an oral contraceptive on the time required to achieve pituitary suppression with gonadotropin-releasing hormone analogues and on subsequent implantation and pregnancy rates. Fertil Steril 1998;70:1063–1069.
Raoofi Z, Afatoonian A: Ovarian cysts formation during depot formulation of GnRH – a therapy and the effect of pretreatment with oral contraceptive pills on subsequent implantation and pregnancy rate in art cycles. Iran J Pharm Res 2008;7:109–113.
Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G: Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12:651–671.
Smulders B, van Oirschot SM, Farquhar C, Rombauts L, Kremer JA: Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques. Cochrane Database Syst Rev CD006109.
Bukulmez O, Yarali H, Yucel A, Sari T, Gurgan T: Intracytoplasmic sperm injection versus in vitro fertilization for patients with a tubal factor as their sole cause of infertility: a prospective, randomized trial. Fertil Steril 2000;73:38–42.
Lunenfeld B, Insler V, Glezerman M: Diagnosis and Treatment of Functional Infertility, ed 3. Berlin, Blackwell Wissenschaft, 1993.
Huirne JA, Hugues JN, Pirard C, Fischl F, Sage JC, Pouly JL, Obruca A, Braat DM, van Loenen AC, Lambalk CB: Cetrorelix in an oral contraceptive-pretreated stimulation cycle compared with buserelin in IVF/ICSI patients treated with R-HFSH: a randomized, multicentre, phase IIIB study. Hum Reprod 2006;21:1408–1415.
Rombauts L, Healy D, Norman RJ: A comparative randomized trial to assess the impact of oral contraceptive pretreatment on follicular growth and hormone profiles in GnRH antagonist-treated patients. Hum Reprod 2006;21:95–103.
Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, Wu GJ, Huang SC, Chen CY, Chen PH, Tzeng CR: Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pretreatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod 2004;19:1993–2000.
Chung MT, Tsai YC, Chen SH, Loo TC, Tang HH, Lin LY: Influence of pituitary suppression with triphasic or monophasic oral contraceptives on the outcome of in vitro fertilization and embryo transfer. J Assist Reprod Genet 2006;23:343–346.
Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z: Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997;12:2359–2365.
Duvan CI, Berker B, Turhan NO, Satiroglu H: Oral contraceptive pretreatment does not improve outcome in microdose gonadotrophin-releasing hormone agonist protocol among poor responder intracytoplasmic sperm injection patients. J Assist Reprod Genet 2008;25:89–93.
Surrey ES, Bower J, Hill DM, Ramsey J, Surrey MW: Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. Fertil Steril 1998;69:419–424.
Pal L, Jindal S, Witt BR, Santoro N: Less is more: increased gonadotropin use for ovarian stimulation adversely influences clinical pregnancy and live birth after in vitro fertilization. Fertil Steril 2008;89:1694–1701.
Hollis S, Campbell F: What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999;319:670–674.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.